LipoScience Rescues Some Value For Shareholders In A Sale To LabCorp
Stephen Simpson, CFA • Fri, Sep. 26
- LipoScience sells itself to LabCorp for $5.25 per share in cash, or less than 2x forward revenue estimates.
- LipoScience didn't have the resources to build a commercially viable business with its LipoProfile test, but the science and benefits are sound and LabCorp can take the test much further.
- LabCorp's offer is fair relative to LipoScience's standalone prospects, even though the deal could well be a meaningful value-builder for LabCorp down the line.